Cigna Corporation (CI) Director William D. Zollars Sells 1,232 Shares
Cigna Corporation (NYSE:CI) Director William D. Zollars sold 1,232 shares of the company’s stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $187.23, for a total transaction of $230,667.36. The transaction was disclosed in a filing with the SEC, which is available at this link.
Cigna Corporation (CI) traded down 1.29% during mid-day trading on Thursday, hitting $185.20. 1,394,542 shares of the stock were exchanged. The stock has a market cap of $46.63 billion, a price-to-earnings ratio of 21.37 and a beta of 0.43. Cigna Corporation has a 52-week low of $115.03 and a 52-week high of $188.36. The stock has a 50 day moving average of $179.12 and a 200-day moving average of $164.84.
Cigna Corporation (NYSE:CI) last issued its earnings results on Friday, August 4th. The health services provider reported $2.91 EPS for the quarter, beating the Zacks’ consensus estimate of $2.48 by $0.43. The firm had revenue of $10.32 billion for the quarter, compared to analyst estimates of $10.26 billion. Cigna Corporation had a return on equity of 17.40% and a net margin of 5.55%. Cigna Corporation’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.98 earnings per share. Equities analysts predict that Cigna Corporation will post $10.02 EPS for the current fiscal year.
CI has been the subject of several research reports. Credit Suisse Group initiated coverage on shares of Cigna Corporation in a report on Monday, June 12th. They issued an “outperform” rating and a $185.00 price objective for the company. Oppenheimer Holdings, Inc. upped their price objective on shares of Cigna Corporation from $174.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, June 15th. Jefferies Group LLC restated a “buy” rating and issued a $190.00 price objective (down from $199.00) on shares of Cigna Corporation in a report on Friday, August 4th. Morgan Stanley initiated coverage on shares of Cigna Corporation in a report on Tuesday, June 6th. They issued an “overweight” rating and a $184.00 price objective for the company. Finally, BidaskClub lowered shares of Cigna Corporation from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $181.65.
A number of hedge funds and other institutional investors have recently modified their holdings of CI. American Beacon Advisors Inc. purchased a new stake in Cigna Corporation in the first quarter valued at approximately $102,000. Capstone Investment Advisors Netherlands B.V. purchased a new stake in Cigna Corporation in the second quarter valued at approximately $106,000. Founders Capital Management purchased a new stake in Cigna Corporation in the first quarter valued at approximately $117,000. Mckinley Capital Management LLC Delaware purchased a new stake in Cigna Corporation in the first quarter valued at approximately $122,000. Finally, Parallel Advisors LLC boosted its position in Cigna Corporation by 62.3% in the second quarter. Parallel Advisors LLC now owns 800 shares of the health services provider’s stock valued at $139,000 after buying an additional 307 shares during the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.
About Cigna Corporation
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Receive News & Ratings for Cigna Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cigna Corporation and related companies with MarketBeat.com's FREE daily email newsletter.